VEGFA Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

All VEGFA reagents are produced in house and quality controlled, including 23 VEGFA Antibody, 3 VEGFA ELISA, 104 VEGFA Gene, 15 VEGFA Lysate, 18 VEGFA Protein, 3 VEGFA qPCR. All VEGFA reagents are ready to use.

VEGFA Antibody (23)

    VEGFA ELISA キット(すぐに使用できます)& ELISA抗体ペアセット(すぐに使用できません)(3)

    VEGFA cDNA Clone (104)

    NM_001171625.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001171628.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001171626.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001287058.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    AY033506.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001278384.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001278385.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    AF133248.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    VEGFA Lysate (15)

      VEGFA の背景知識

      Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.

      VEGFA の参考文献

      • Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
      • Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
      • Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
      • Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
      • Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
      • Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.